NEW YORK (GenomeWeb) – Abbott reported on Wednesday that its fourth quarter diagnostic revenues grew 3 percent year over year, despite an unfavorable 1 percent effect from foreign exchange.

Its molecular diagnostics revenues dropped 8 percent driven by a planned scale down of its genetics business that offset growth in infectious disease testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.